How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison with Vabysmo has reported. The question now carries a large price tag. Johnson & Johnson agreed on 16 November 2026 to acquire Ollin Biosciences, the antibody’s developer.
What J&J is buying with Ollin
J&J will pay $2.2bn upfront for Ollin, a venture-backed company based in Austin, Texas. Ollin shareholders can receive up to about $1.125bn more in regulatory and commercial milestones. The companies expect the deal to close before the end of 2026, subject to regulatory approvals. A separate article sets out the full Ollin acquisition terms.
In parallel, Blackstone Life Sciences will pay J&J $750m over several years. That money is meant to fund Phase 3 development in full. In return, Blackstone is eligible for regulatory and sales milestones and single-digit royalties. The funding agreement takes effect only if the acquisition closes, according to the J&J announcement.
The asset is a bispecific antibody against VEGF and angiopoietin-2 (Ang2). Innovent Biologics discovered it under the code IBI324 and co-develops it with Ollin. Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson, commented in the release. He said the antibody “selectively targets two important drivers of retinal disease”.
Ollin itself is young. It raised a $330m Series B in June 2026, co-led by TCGX and ARCH Venture Partners. It said the money would fund a registrational programme for OLN324 in both target diseases. Innovent had earlier described the antibody as a higher-potency, higher-molar-dose design. Its stated aim was better anatomy and longer durability than current standards such as faricimab.
J&J does not currently sell a retinal disease drug, BioSpace reported. The molecule also adds to a year of cross-border dealmaking in Chinese-discovered assets. Those deals are logged in the China out-licensing deals tracker.
How does OLN324 compare with Vabysmo in the JADE trial?
The comparison rests on JADE, a randomised Phase 1b study run at US sites. It enrolled 164 patients with diabetic macular oedema (DMO) or wet age-related macular degeneration (AMD). Patients received three monthly injections of OLN324 2 mg, OLN324 4 mg or faricimab 6 mg. Faricimab is the active ingredient in Roche’s Vabysmo. Patients were then followed for 12 weeks off treatment, with retreatment under the same protocol criteria for every arm.
Diabetic macular oedema
In DMO, Ollin reported faster and greater retinal drying than with faricimab. At week 1, mean central subfield thickness fell by 79 µm on the 4 mg dose. The fall on faricimab was 45 µm. By week 12, the reductions were 180 µm and 121 µm respectively, according to Ollin’s January topline release.
Nearly 90 per cent of DMO patients on the 4 mg dose had no oedema at week 12. The study defined that as central thickness below 325 µm. The figure on faricimab was 57 per cent. Veeral Sheth of University Retina and Macula Associates later presented the 83-patient DMO cohort at ASRS in July. Ophthalmology Times reported rates of 88.5 per cent on 4 mg and 84.6 per cent on 2 mg. The faricimab rate was 57.1 per cent. It cited a nominal p value of 0.003.
The durability gap was narrower. Through 12 weeks off treatment, 93 per cent of 4 mg patients needed no retreatment. The faricimab figure was 89 per cent. Vision gains were numerically greater on the bispecific. Even so, Ollin has not released letter scores for the DMO cohort.
Wet AMD
In wet AMD, retinal drying was rapid and comparable between the two drugs. At week 12, Ollin reported about 50 per cent greater reductions in pigment epithelial detachment on 4 mg. At week 20, mean best-corrected visual acuity favoured the 4 mg dose by 2.2 letters. Retreatment-free rates were 82 per cent and 81 per cent, according to Ollin’s final JADE data release in March.
Safety findings so far
No intraocular inflammation occurred in either OLN324 arm, while one case occurred on faricimab. Ollin also reported no retinal vasculitis or occlusive retinal vasculitis on its antibody. On the other hand, the March release did not report serious adverse events or other adverse event rates. Ophthalmology Times reported no treatment-related serious adverse events in any arm at ASRS.
A single inflammation case in a small trial cannot establish a safety difference. For context, the UK summary of product characteristics for Vabysmo lists uveitis, iritis, iridocyclitis and vitritis as uncommon. It lists retinal vasculitis and occlusive retinal vasculitis at unknown frequency, from post-marketing reports. That text was last revised on 20 August 2026.
What the JADE data cannot answer yet
JADE was small, short and run only in the US. Every patient had three loading doses and then a fixed 12-week observation window. By contrast, the UK Vabysmo label describes treat-and-extend dosing in steps of up to four weeks. It notes that intervals beyond 16 weeks have not been studied. JADE therefore did not test faricimab at the longer intervals used in practice. Ollin has also not published per-arm sample sizes or most p values.
The registrational question is different, too. Several Phase 3 studies have been registered, including GOBI (NCT07842016). It compares OLN324 with aflibercept in an estimated 450 adults with DMO. A registry listing viewed on 17 November 2026 showed it as not yet enrolling. No Phase 3 trial against faricimab could be confirmed that day. Unless one is added, the pivotal programme may not answer the Vabysmo question directly.
When could OLN324 reach patients?
There is no filing date yet. J&J describes the antibody as a Phase 3 asset. Ollin had planned to start global Phase 3 trials in the second half of 2026. In June, Ollin said it had completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). It also said it had received scientific advice from the European Medicines Agency (EMA) on the Phase 3 programme.
Ollin expects recruitment in North America, South America, Europe and Japan, subject to regulatory communications. Neither company has given a filing or approval timeline. The next markers will be first-patient-dosed news for GOBI and a wet AMD trial. After that, registry completion dates will show when pivotal data could arrive.
What the deal means for the UK and the anti-VEGF market
Vabysmo is the incumbent that any newcomer must displace. The FDA approved it in January 2022 for wet AMD and diabetic macular oedema. Genentech described it then as the first bispecific antibody for the eye. In the UK, its first authorisation dates from 16 May 2022. The UK label now also covers retinal vein occlusion. Meanwhile, Roche reported Vabysmo sales of CHF 3,196m in the first nine months of 2026. That was up 10 per cent at constant exchange rates.
In England, NHS access would run through NICE. Its appraisal of faricimab in wet AMD recommends the drug only within set visual acuity and lesion criteria. It also tells clinicians to choose the least expensive suitable treatment. A new entrant would therefore face a cost test as well as a clinical one. Earlier coverage of diabetic macular oedema treatment set out how the two leading drugs compete. Faricimab and aflibercept 8 mg are judged largely on injection frequency.
For now, the answer is mixed. OLN324 showed faster anatomical drying in DMO in a small trial. Its advantages on vision and retreatment-free intervals were modest. Phase 3 trials, starting with one against aflibercept, will decide whether J&J’s $2.2bn bet translates into fewer injections.














